Supernus Pharmaceuticals Inc R&D Day Transcript
Okay. Good morning, and thank you so much for joining us today. We're very excited about the R&D Day and what we're going to be sharing with you about the future of Supernus.
Now before I get started, I just want to remind everyone that we will be making forward-looking statements throughout the day, so please check our SEC filings for all the risk factors associated with our business.
As far as our agenda today, I'll be making very brief introductions and going through a brief corporate overview, and then we'll get into the details behind some of the key product candidates that we have in our pipeline. We will have a couple of slides on Qelbree at the beginning in the R&D setting, and then we'll get into 820 -- SPN-820 for depression. We'll have a small Q&A session behind 820. We'll get into the details behind SPN-817. We'll also have a Q&A session after that. And then we will share with you some early data we have on SPN-443 for ADHD and SPN-446 for narcolepsy. And we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
